Overview of adrenergic anorectic agents.
Overview of adrenergic anorectic agents.
复制标题
肾上腺素能食欲抑制剂概述。
DOI：
--
复制
发表时间：
1992
影响因子：
7.1
通讯作者：
P. Wellman
中科院分区：
文献类型：
--
作者：
P. Wellman
安非他明类的肾上腺素能抑制剂通过激活穹窿周围下丘脑（PFH）内的β-肾上腺素能和/或多巴胺能受体来抑制食欲并减轻体重。虽然苯丙醇胺（PPA）通常被认为是安非他明类兴奋剂的成员，但这种药物是一种非典型的肾上腺素能兴奋剂。与安非他明不同，将PPA微量注射到PFH中不会抑制进食。此外，PPA厌食症不能被多巴胺拮抗剂氟哌啶醇逆转。PPA的降压作用可能部分是由于其与室旁内侧下丘脑（PVN）内α 1肾上腺素能受体的相互作用。这一假设得到了先前研究的支持，该研究证明PPA是主要针对α 1肾上腺素受体的直接作用激动剂，向PVN中微量注射α 1肾上腺素受体激动剂PPA和l-苯肾上腺素抑制进食，并且在PVN内注射α 1肾上腺素受体拮抗剂增强进食行为。
Adrenergic anorexic agents of the amphetamine class suppress appetite and reduce body weight via activation of beta-adrenergic and/or dopaminergic receptors within the perifornical hypothalamus (PFH). Although phenylpropanolamine (PPA) is often considered to be a member of the amphetamine class of anorexiants, this drug is an atypical adrenergic anorexiant. Unlike amphetamine, microinjection of PPA into the PFH does not suppress feeding. Moreover, PPA anorexia is not reversed by the dopamine antagonist haloperidol. The anorexic action of PPA may result, in part, from its interaction with alpha 1-adrenergic receptors within the paraventricular medial hypothalamus (PVN). This hypothesis is supported by prior research, which documents that PPA is a direct-acting agonist predominantly at alpha 1 adrenoceptors, that microinjections into the PVN of the alpha 1-adrenoceptor agonists PPA and l-phenylephrine suppress feeding, and that injections of alpha 1-adrenoceptor antagonists within the PVN enhance feeding behavior.